Inhibition of ADP-ribosyl cyclase attenuates angiotensin II-induced cardiac hypertrophy

Cardiovascular Research

Volumn 81, Issue 3, 2009, Pages 582-591

  Gul, Rukhsana ^a   Park, Jae Hyeong ^b   Kim, Seon Young ^a   Jang, Kyu Yoon ^a   Chae, Jei Keon ^a   Ko, Jae Ki ^a   Kim, Uh Hyun ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

ADPR cyclase; Angiotensin II; Ca2+; Cardiac hypertrophy; Cardiomyocytes

Indexed keywords

2,2' DIHYDROXYAZOBENZENE; 4 DIMETHYLAMINOAZOBENZENE; 8 BROMO CYCLIC ADENOSINE DIPHOSPHATE RIBOSE; ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; ANGIOTENSIN II; BLOCKING AGENT; CALCIUM ION; CYCLIC ADENOSINE DIPHOSPHATE RIBOSE; ENZYME INHIBITOR; GROWTH FACTOR; INOSITOL TRISPHOSPHATE; NUCLEAR FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL LEVEL; CELL VOLUME; CONFOCAL MICROSCOPY; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; IN VITRO STUDY; MALE; MEDIATOR; MICROSCOPE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; RAT STRAIN; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; T LYMPHOCYTE ACTIVATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADP-RIBOSYL CYCLASE; ANGIOTENSIN II; ANIMALS; AZO COMPOUNDS; CALCIUM; CALCIUM SIGNALING; CARDIOMEGALY; CELL SIZE; CYCLIC ADP-RIBOSE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYPERTENSION, RENOVASCULAR; MALE; MYOCYTES, CARDIAC; NEPHRECTOMY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RENAL ARTERY; SRC-FAMILY KINASES;

EID: 59449101929     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn232     Document Type: Article

References (29)

1. De Toledo FGS, Cheng J, Liang M, Chini EN, Dousa TP. ADP-ribosyl cyclase in rat vascular smooth muscle cells properties and regulation. Circ Res 2000;86:1153-1159.
2. 2+ signaling. Adv Exp Med Biol 1997;419:411-419.
3. Kato I, Takasawa S, Akabane A, Tanaka O, Abe H, Takamura T et al. Regulatory role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic beta cells. Enhanced insulin secretion in CD38-expressing transgenic mice. J Biol Chem 1995;270:30045-30050.
4. Okamoto H, Takasawa S, Nata K, Kato I, Tohgo A, Noguchi N. Physiological and pathological significance of the CD38-cyclic ADP-ribose signaling system. Chem Immunol 2000;75:121-145.
5. 2+ signaling contributes to airway smooth muscle hyper-responsiveness. FASEB J 2003;17:452-454.
6. Jin D, Liu HX, Hirai H, Torashima T, Nagai T, Lopatina O et al. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 2007;446:41-45.
7. Partida-Sanchez S, Cockayne DA, Monard S, Jacobson EL, Oppenheimer N, Garvy B et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med 2001;11:1209-1216.
8. +-glycohydrolase in brain from CD38-deficient mice. J Biol Chem 2003;278:40670-40678.
9. Nam TS, Choi SH, Rah SY, Kim SY, Kim WJ, Im MJ et al. Discovery of a small-molecule inhibitor for kidney ADP-ribosyl cyclase: implication for intracellular calcium signal mediated by cyclic ADP-ribose. Exp Mol Med 2006;38:718-726.
10. Xie GH, Rah SY, Kim SJ, Nam TS, Ha KC, Chae SW et al. ADP-ribosyl cyclase couples to cAMP signaling in the cardiomyocytes. Biochem Biophys Res Commun 2005;330:1290-1298.
11. Gul R, Kim SY, Park KH, Kim BJ, Im MJ, Kim SJ et al. A novel signaling pathway of ADP-ribosyl cyclase activation by angiotensin II in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol 2008;295:H77- H88.
12. Parsons KK, Coffman TM. The renin-angiotensin system: it's all in your head. J Clin Invest 2007;117:873-876.
13. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007;17:568-575.
14. Kim SY, Gul R, Rah SY, Kim SH, Park SK, Im MJ et al. Molecular mechanism of ADP-ribosyl cyclase activation in angiotensin II signaling in murine mesangial cells. Am J Physiol Renal Physiol 2008;294:F982- F989.
15. 2+ level and motility of lymphokine-activated killer cells. J Biol Chem 2005;280:2888-2895.
16. Murat A, Pellieux C, Brunner HR, Pedrazzini T. Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem 2000;275:40867-40873.
17. Dipp M, Evans AM. Cyclic ADP-ribose is the primary trigger for hypoxic pulmonary vasoconstriction in the rat lung in situ. Circ Res 2001;89:77-83.
18. Rakovic S, Galione A, Ashamu GA, Potter BV, Terrar DA. A specific cyclic ADP-ribose antagonist inhibits cardiac excitation-contraction coupling. Curr Biol 1996;6:989-996.
19. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228.
20. Li HL, Wang AB, Huang Y, Liu DP, Liu G, Zhang CN et al. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med 2005;38:243-257.
21. Iijima K, Yoshizumi M, Hashimoto M, Kim S, Eto M, Ako J et al. Red wine polyphenols inhibit proliferation of vascular smooth muscle cells and downregulate expression of cyclin A gne. Circulation 2000;101:805- 811.
22. Makino T, Ono T, Muso E, Yoshida H, Honda G, Sasayama S. Inhibitory effects of rosmarinic acid on the proliferation of cultured murine mesangial cells. Nephrol Dial Transplant 2000;15:1140-1145.
23. Graeff RM, Walseth TF, Fryxell K, Branton WD, Lee HC. Enzymatic synthesis and characterizations of cyclic GDP-ribose. A procedure for distinguishing enzymes with ADP-ribosyl cyclase activity. J Biol Chem 1994;269:30260-30267.
24. Schultz JEJ, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL et al. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002;109:787-796.
25. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79.
26. Shorofsky SR, Aggarwal R, Corretti M, Baffa JM, Strum JM, Strum JM et al. Cellular mechanisms of altered contractility in the hypertrophied heart: big hearts, big sparks. Circ Res 1999;84:424-434.
27. 2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 2000;106:1351-1359.
28. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989;13:305-314.
29. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1. Am J Physiol Heart Circ Physiol 2002;283:H1253-H1262.